{"id":247320,"date":"2013-05-21T16:46:09","date_gmt":"2013-05-21T20:46:09","guid":{"rendered":"http:\/\/www.eugenesis.com\/volcano-to-highlight-its-physiology-expansion-efforts-at-europcr-2013\/"},"modified":"2013-05-21T16:46:09","modified_gmt":"2013-05-21T20:46:09","slug":"volcano-to-highlight-its-physiology-expansion-efforts-at-europcr-2013","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/physiology\/volcano-to-highlight-its-physiology-expansion-efforts-at-europcr-2013.php","title":{"rendered":"Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013"},"content":{"rendered":"<p><p>    SAN DIEGO, May 20, 2013 \/PRNewswire\/ --Volcano    Corporation (VOLC)    a leading developer and manufacturer of precision guided    therapy tools designed to enhance the diagnosis and treatment    of coronary and peripheral vascular disease, today announced it    will highlight its efforts to expand research and innovation    surrounding its physiology technologies, including its    Fractional Flow Reserve (FFR) and iFR (Instant    Wave-Free Ratio)1 technologies, via various    clinical and educational presentations and events at EuroPCR    2013 in Paris.  <\/p>\n<p>    \"Volcano is committed to making clinical and technological    advances that expand access to functional management,\"    commented Michele Perrino, president of Europe, Middle East,    Africa, and India Operations of Volcano. \"Our focus at EuroPCR    is to introduce our latest functional management technologies    and clinical data, and demonstrate their potential to improve    both patient care and the experience for our physician partners    in Europe. Given our commitment to provide physicians with    choice, we are excited to feature iFR, our novel    hyperemia-free software modality, and our Verrata Pressure    Guide Wire, which upon regulatory clearance will be our fifth    new guide wire in five years.\"2  <\/p>\n<p>    Volcano will formally launch its iFR modality and    CORE Integrated System, and display the Verrata    Wire at the conference. Volcano will showcase its future and    currently available physiology, imaging, and multi-modality    systems products in the company's exhibit hall booth #M71.  <\/p>\n<p>    Featured events for Volcano include four live case symposia    demonstrating the benefits of incorporating both FFR and our    iFR modality in simple and complex cases, the    presentation of the findings from the Adenosine Vasodilator    Independent Stenosis Evaluation II (ADVISE II) study data at a    hot line session, and over 10 scientific podium presentations    featuring advanced physiology using Volcano products.  <\/p>\n<p>    Key EventsWednesday, May 22, 10:50  11:30 a.m.    Complex bifurcation stenting: LIVE demonstration of emerging    techniquesLIVE iFR demonstration from    Erasmus University Medical Center, Thorax Center  Rotterdam,    The Netherlands    Theatre Bleu  <\/p>\n<p>    Thursday, May 23, 9:45 - 11:45 a.m.    Adenosine Vasodilator Independent Stenosis Evaluation II    (ADVISE II)Hot Line - Evolving procedural    strategies    Room    351  <\/p>\n<p>    Thursday, May 23, 4:45  6:45 p.m.    Physiological Stenosis Assessment with FFR and Instant    Wave-Free Ratio: We Need Both!Live case demonstrations    (simple and multivessel disease) from St. Thomas' Hospital,    London, followed by panel discussions    Theatre Bordeaux  <\/p>\n<p>    Friday, May 24, 9:00  12:30 p.m.    Complex cardiovascular interventions and new techniques     Master LIVE demonstrations Continuous LIVE FFR and    iFR demonstrations from Sunninghill and Sunward    Park Hospitals, South Africa and St Thomas' Hospital  London,    United Kingdom    Main Arena  <\/p>\n<p>    Daily, 12:00  3:00 p.m.    Meet the iFR Experts Booth #M71  <\/p>\n<p>    About Volcano Corporation Volcano Corporation is    revolutionizing the medical device industry with a broad suite    of technologies that make imaging and therapy simpler, more    informative and less invasive. Its products empower physicians    around the world with a new generation of analytical tools that    deliver more meaningful information - using sound and light as    the guiding elements. Founded in cardiovascular care and    expanding into other specialties, Volcano is changing the    assumption about what is possible in improving patient outcomes    by combining imaging and therapy together.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>See more here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/volcano-highlight-physiology-expansion-efforts-003800033.html;_ylt=AwrNUbH53JtREzcAFd__wgt.\" title=\"Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013\">Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SAN DIEGO, May 20, 2013 \/PRNewswire\/ --Volcano Corporation (VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will highlight its efforts to expand research and innovation surrounding its physiology technologies, including its Fractional Flow Reserve (FFR) and iFR (Instant Wave-Free Ratio)1 technologies, via various clinical and educational presentations and events at EuroPCR 2013 in Paris.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/physiology\/volcano-to-highlight-its-physiology-expansion-efforts-at-europcr-2013.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577488],"tags":[],"class_list":["post-247320","post","type-post","status-publish","format-standard","hentry","category-physiology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/247320"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=247320"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/247320\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=247320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=247320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=247320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}